Drug Detail

Drug Name Palbociclib
Trade Name Ibrance
Synonyms PD0332991
Drug Descriptions

Ibrance (palbociclib) is a selective inhibitor of cyclin-dependent kinase 4 (CDK4) and 6 (CDK6) (PMID: 19874578). Ibrance (palbociclib) is approved in combination with an aromatase inhibitor in postmenopausal patients with ER-positive, ERBB2 (HER2)-negative metastatic breast cancer, and in combination with Faslodex (fulvestrant) in patients with ER-positive, ERBB2 (HER2)-negative metastatic breast cancer (FDA.gov).

DrugClasses CDK4/6 Inhibitor 8

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Therapy Description
Bortezomib + Dasatinib + Dexamethasone + Doxorubicin + Palbociclib
Carboplatin + Palbociclib
Palbociclib Ibrance (palbociclib) is a selective inhibitor of cyclin-dependent kinase 4 (CDK4) and 6 (CDK6) (PMID: 19874578). Ibrance (palbociclib) is approved in combination with an aromatase inhibitor in postmenopausal patients with ER-positive, ERBB2 (HER2)-negative metastatic breast cancer, and in combination with Faslodex (fulvestrant) in patients with ER-positive, ERBB2 (HER2)-negative metastatic breast cancer (FDA.gov).
Palbociclib + PF-04691502
Bosutinib + Fulvestrant + Palbociclib
Palbociclib + Sorafenib
Palbociclib + Pimasertib
GSK461364 + PD0332991
Anastrozole + Palbociclib + Pertuzumab + Trastuzumab
Ibrutinib + Palbociclib
Anastrozole + Palbociclib
Palbociclib + Quizartinib
Letrozole + Palbociclib + Trastuzumab
Palbociclib + Sirolimus
Exemestane + Everolimus + Palbociclib
MK2206 + Palbociclib
Palbociclib + Cetuximab
Palbociclib + Tamoxifen
Palbociclib + RAD140
Letrozole + Palbociclib + Tucatinib
Palbociclib + XAV939
H3B-5942 + Palbociclib
GDC-0077 + Letrozole + Palbociclib
PD0332991 + BEZ235
PD-0325901 + Palbociclib
Erdafitinib + Fulvestrant + Palbociclib
GDC-9545 + Palbociclib
Alvocidib + Palbociclib
Copanlisib + Palbociclib + Letrozole
Fulvestrant + Palbociclib + Pictilisib
H3B-6527 + Palbociclib
Fulvestrant + Olaparib + Palbociclib
Bicalutamide + Palbociclib
Palbociclib + Trastuzumab
Fulvestrant + Palbociclib + Avelumab
AZD9833 + Palbociclib LImited information is currently available on AZD9833 (Nov, 2018).
Gedatolisib + Palbociclib
Palbociclib + Tandutinib
ON-01910 + PD0332991
Palbociclib + Velcade
Everolimus + Palbociclib
D-0502 + Palbociclib
AZD8835 + Fulvestrant + Palbociclib
Letrozole + Palbociclib + PF-06952229
Palbociclib + PD173074
Buparlisib + Palbociclib
Palbociclib + Dexamethasone
PD0332991 + 5-FU
AZD9496 + Palbociclib
PD0332991 + GDC0980
Linsitinib + Palbociclib
GSK2194069 + Palbociclib
Palbociclib + Fluorouracil + Oxaliplatin
Palbociclib + Ulixertinib
Ado-trastuzumab emtansine + Letrozole + Palbociclib
Lapatinib + Palbociclib
pipendoxifene + palbociclib
Avelumab + Palbociclib + Tamoxifen
Exemestane + Palbociclib
Bosutinib + Palbociclib
PD-0332991 + T-DM1
PD0332991 + AZD8055
GSK2334470 + Palbociclib
Palbociclib + SAR439859
Hydroxychloroquine + Letrozole + Palbociclib Plaquenil (hydroxychloroquine sulfate) increases intralysosomal pH, resulting in inhibition of autophagic protein degradation and accumulation of autophagosomes, which potentially leads to cell death in autophagy-dependent tumor cells (NCI Drug Dictionary).
Palbociclib + Tanespimycin
Letrozole + Palbociclib + Pembrolizumab
AZD8835 + Palbociclib
Cisplatin + Palbociclib
Bazedoxifene + Palbociclib
Goserelin + Letrozole + Palbociclib
Palbociclib + Trametinib
Palbociclib + SGI-1776
Palbociclib + Decitabine
Fulvestrant + Palbociclib
Fulvestrant + Letrozole + Palbociclib
PD0332991 + Gemcitabine
PD0332991 + AZD6244
Neratinib + Palbociclib
Palbociclib + TCS 359
Palbociclib + Vorinostat
Binimetinib + Palbociclib
Palbociclib + Pictilisib
Palbociclib + Vemurafenib Ibrance (palbociclib) is a selective inhibitor of cyclin-dependent kinase 4 (CDK4) and 6 (CDK6) (PMID: 19874578). Ibrance (palbociclib) is approved, in combination with Femara (letrozole), in ER positive, HER2 negative metastatic breast cancer (FDA.gov).
Avelumab + Axitinib + Palbociclib
nab-paclitaxel + Palbociclib
Palbociclib + ZN-c5
Palbociclib + Letrozole
HMN-214 + PD0332991
Avelumab + Cetuximab + Palbociclib